Brentuximab vedotin in patients with Hodgkin Lymphoma and a failed allogeneic stem cell transplantation: Results from a named patient program at four italian centers

Carmelo Carlo-Stella, Francesca Rcci, S. Erena Dalto, Rita Mazza, Michele Malagola, Francesca Patriarca, Simonetta Viviani, Domenico Russo, Laura Giordano, Luca Castagna, Paolo Corradini, Armando Santoro

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background. Brentuximab vedotin (BV) has demonstrated an extraordinary efficacy in heavily pretreated classical Hodgkin lymphoma (cHL) patients, targeting CD30-positive cells; however, limited data have been reported on the efficacy of BV in cHL patients failing allogeneic stem cell transplantation (allo-SCT).The aim of this study was to retrospectively evaluate the efficacy and safety of BV in a multicenter setting of cHL relapsing or progressing after allo-SCT. Methods. Sixteen BV-na¨ve patients with recurrent cHL after allo-SCT were included in a compassionate use program and treated with intravenous BV at the dose of 1.8 mg/kg of body weight every 3 weeks for a maximum of 16 cycles. Results. The objective response rate was 69%. Five patients (31%) had complete remission, and 6 (37%) had partial remission. Stable disease was observed in 4 patients (25%), and progressive disease was observed in 1 (6%). After median follow-up of 26 months (range: 5-30 months), median progression-free survival (PFS), overall survival (OS), and duration of response were 7, 25, and 5 months, respectively. The 2-year PFS and OS were 20% and 61%, respectively. Grade 3-4 hematological adverse events included anemia (15%), thrombocytopenia (12%), and neutropenia (18%). Grade 3 peripheral sensory neuropathy occurred in 2 patients (12%). Conclusion. BV therapy is an effective and safe approach for achieving transient disease control in cHL patients with failed allo-SCT. To improve disease control, future studies should explore the combination of BV with targeted agents.

Original languageEnglish
Pages (from-to)323-328
Number of pages6
JournalThe oncologist
Volume20
Issue number3
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Stem Cell Transplantation
Hodgkin Disease
Disease-Free Survival
Compassionate Use Trials
Survival
Peripheral Nervous System Diseases
cAC10-vcMMAE
Neutropenia
Thrombocytopenia
Anemia
Body Weight
Safety

Keywords

  • Allogeneic stem cell transplantation
  • Brentuximab vedotin
  • CD30
  • Relapsed or refractory Hodgkin lymphoma
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{1f9e7b19a7f249a480c7d7619462e3fc,
title = "Brentuximab vedotin in patients with Hodgkin Lymphoma and a failed allogeneic stem cell transplantation: Results from a named patient program at four italian centers",
abstract = "Background. Brentuximab vedotin (BV) has demonstrated an extraordinary efficacy in heavily pretreated classical Hodgkin lymphoma (cHL) patients, targeting CD30-positive cells; however, limited data have been reported on the efficacy of BV in cHL patients failing allogeneic stem cell transplantation (allo-SCT).The aim of this study was to retrospectively evaluate the efficacy and safety of BV in a multicenter setting of cHL relapsing or progressing after allo-SCT. Methods. Sixteen BV-na¨ve patients with recurrent cHL after allo-SCT were included in a compassionate use program and treated with intravenous BV at the dose of 1.8 mg/kg of body weight every 3 weeks for a maximum of 16 cycles. Results. The objective response rate was 69{\%}. Five patients (31{\%}) had complete remission, and 6 (37{\%}) had partial remission. Stable disease was observed in 4 patients (25{\%}), and progressive disease was observed in 1 (6{\%}). After median follow-up of 26 months (range: 5-30 months), median progression-free survival (PFS), overall survival (OS), and duration of response were 7, 25, and 5 months, respectively. The 2-year PFS and OS were 20{\%} and 61{\%}, respectively. Grade 3-4 hematological adverse events included anemia (15{\%}), thrombocytopenia (12{\%}), and neutropenia (18{\%}). Grade 3 peripheral sensory neuropathy occurred in 2 patients (12{\%}). Conclusion. BV therapy is an effective and safe approach for achieving transient disease control in cHL patients with failed allo-SCT. To improve disease control, future studies should explore the combination of BV with targeted agents.",
keywords = "Allogeneic stem cell transplantation, Brentuximab vedotin, CD30, Relapsed or refractory Hodgkin lymphoma, Targeted therapy",
author = "Carmelo Carlo-Stella and Francesca Rcci and Dalto, {S. Erena} and Rita Mazza and Michele Malagola and Francesca Patriarca and Simonetta Viviani and Domenico Russo and Laura Giordano and Luca Castagna and Paolo Corradini and Armando Santoro",
year = "2015",
month = "3",
day = "1",
doi = "10.1634/theoncologist.2014-0420",
language = "English",
volume = "20",
pages = "323--328",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "3",

}

TY - JOUR

T1 - Brentuximab vedotin in patients with Hodgkin Lymphoma and a failed allogeneic stem cell transplantation

T2 - Results from a named patient program at four italian centers

AU - Carlo-Stella, Carmelo

AU - Rcci, Francesca

AU - Dalto, S. Erena

AU - Mazza, Rita

AU - Malagola, Michele

AU - Patriarca, Francesca

AU - Viviani, Simonetta

AU - Russo, Domenico

AU - Giordano, Laura

AU - Castagna, Luca

AU - Corradini, Paolo

AU - Santoro, Armando

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background. Brentuximab vedotin (BV) has demonstrated an extraordinary efficacy in heavily pretreated classical Hodgkin lymphoma (cHL) patients, targeting CD30-positive cells; however, limited data have been reported on the efficacy of BV in cHL patients failing allogeneic stem cell transplantation (allo-SCT).The aim of this study was to retrospectively evaluate the efficacy and safety of BV in a multicenter setting of cHL relapsing or progressing after allo-SCT. Methods. Sixteen BV-na¨ve patients with recurrent cHL after allo-SCT were included in a compassionate use program and treated with intravenous BV at the dose of 1.8 mg/kg of body weight every 3 weeks for a maximum of 16 cycles. Results. The objective response rate was 69%. Five patients (31%) had complete remission, and 6 (37%) had partial remission. Stable disease was observed in 4 patients (25%), and progressive disease was observed in 1 (6%). After median follow-up of 26 months (range: 5-30 months), median progression-free survival (PFS), overall survival (OS), and duration of response were 7, 25, and 5 months, respectively. The 2-year PFS and OS were 20% and 61%, respectively. Grade 3-4 hematological adverse events included anemia (15%), thrombocytopenia (12%), and neutropenia (18%). Grade 3 peripheral sensory neuropathy occurred in 2 patients (12%). Conclusion. BV therapy is an effective and safe approach for achieving transient disease control in cHL patients with failed allo-SCT. To improve disease control, future studies should explore the combination of BV with targeted agents.

AB - Background. Brentuximab vedotin (BV) has demonstrated an extraordinary efficacy in heavily pretreated classical Hodgkin lymphoma (cHL) patients, targeting CD30-positive cells; however, limited data have been reported on the efficacy of BV in cHL patients failing allogeneic stem cell transplantation (allo-SCT).The aim of this study was to retrospectively evaluate the efficacy and safety of BV in a multicenter setting of cHL relapsing or progressing after allo-SCT. Methods. Sixteen BV-na¨ve patients with recurrent cHL after allo-SCT were included in a compassionate use program and treated with intravenous BV at the dose of 1.8 mg/kg of body weight every 3 weeks for a maximum of 16 cycles. Results. The objective response rate was 69%. Five patients (31%) had complete remission, and 6 (37%) had partial remission. Stable disease was observed in 4 patients (25%), and progressive disease was observed in 1 (6%). After median follow-up of 26 months (range: 5-30 months), median progression-free survival (PFS), overall survival (OS), and duration of response were 7, 25, and 5 months, respectively. The 2-year PFS and OS were 20% and 61%, respectively. Grade 3-4 hematological adverse events included anemia (15%), thrombocytopenia (12%), and neutropenia (18%). Grade 3 peripheral sensory neuropathy occurred in 2 patients (12%). Conclusion. BV therapy is an effective and safe approach for achieving transient disease control in cHL patients with failed allo-SCT. To improve disease control, future studies should explore the combination of BV with targeted agents.

KW - Allogeneic stem cell transplantation

KW - Brentuximab vedotin

KW - CD30

KW - Relapsed or refractory Hodgkin lymphoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84925454228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925454228&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2014-0420

DO - 10.1634/theoncologist.2014-0420

M3 - Article

C2 - 25669663

AN - SCOPUS:84925454228

VL - 20

SP - 323

EP - 328

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 3

ER -